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A literature review was performed to investigate the potential role of bisphosphonates 
for the treatment of stress fractures in athletes. Given the inhibitory action on 
osteoclast-mediated bone resorption, short-term suppression of bone remodeling using 
bisphosphonates could potentially treat stress fractures and prevent stress fractures from 
becoming regular fractures. To date, while there are some animal studies showing the 
scientific basis of bisphosphonates on stress fractures, there is still no conclusive 
evidence to prove any effect of bisphosphonates on stress fracture healing in humans. 
Further well-designed clinical trials should be carried out to establish their usefulness 
and safety. Until the results are available, it is prudent to limit the use of 
bisphosphonates for the treatment of stress fractures. 
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Stress fractures are a major problem for athletic and military populations. Hame et al. 
[28] found a stress fracture incidence of 1.4% in collegiate athletes over a 15-year 
observation period. Moreover, the incidence of stress fractures among infantry units of 
the Finnish Army was 8.4% [78], while the incidence of stress fractures among Israeli 
elite infantry recruits over 14 weeks of basic training was 16–25%, as diagnosed by 
scintigraphy on the basis of clinical suspicion [48]. 
A slow healing process may interrupt participation in physical activity for a relatively 
long time period. Also, conservative treatment does not always lead to healing and may 
result in delayed union or nonunion. In certain circumstances, surgical treatment may 
allow a quicker return to activity, but the healing process cannot readily be accelerated. 
Consequently, there is interest in developing an effective pharmacologic intervention to 
either prevent stress fractures or accelerate recovery after a stress fracture occurs. Until 
recently, pharmaceutical agents were prescribed only for the treatment of inflammation 
and pain rather than to promote more rapid healing of stress fractures. 
Although the pathogenesis of stress fractures is not fully understood, development of 
such a fracture likely represents a failure of functional adaptation [8, 18]. Accumulation 





initiation. This is the first step in the pathogenesis of a stress fracture. If such an initial 
process is inadequately repaired, it can lead to crack propagation [59]. Stress fractures 
in athletes and military recruits are the result of either fatigue failure secondary to high 
strains or strain rates, or mediated through a bone remodeling response whereby the 
bone attempts to strengthen itself when subjected to high strains or strain rates, or new 
strain patterns. Milgrom et al. [49] have shown in their in vivo human bone strain gauge 
study that tibial stress fractures are likely due to bone remodeling, while metatarsal 
stress fractures are caused by cyclic overloading alone. 
Over the past decade, bisphosphonates have been widely used to treat a variety of bone 
diseases and have been shown to increase bone mass and decrease fracture risk in 
postmenopausal, osteoporotic women. The marked inhibitory action of bisphosphonates 
on osteoclast-mediated bone resorption has also led to successful treatment of 
pathologic processes associated with increased bone remodeling such as Paget’s disease, 
bone tumors, and metastases. Given their inhibitory action on osteoclast activity, 
short-term suppression of bone remodeling using bisphosphonates could prevent the 
initial bone loss observed during the remodeling response to high bone strains and 
potentially prevent stress fractures [19]. This concept is not new. Physicians have 





this is controversial and has not been well investigated [3, 24]. 
The present review summarizes and discusses the current understanding and the 
potential role of bisphosphonates for the treatment and prevention of stress fractures in 
athletes. 
 
Pathogenesis of stress fractures and the relationship to bisphosphonates 
As stated above, stress fractures occur when a bone fails to remodel adequately 
following the application of repetitive sub-threshold stress. The first stage of bone 
remodeling involves bone resorption, which further weakens the already compromised 
bone [19]. A mathematical model proposes that the porosity introduced by remodeling 
contributes to an unstable situation in which a stress fracture will occur [44]. 
Experimental studies with a rabbit impulsive loading model [17] also suggested that a 
positive feedback between loading and remodeling might be a feature of stress fracture 
pathogenesis. By 6 weeks of loading, activation of new bone remodeling had increased 
further still and there was a 10-fold increase in bone microdamage. The incidence of 
overt stress fractures in these animals had increased to 68% after 6 weeks. These data 
suggest that overloading first creates a biological remodeling response, which is 





acceleration of bone microdamage accumulation, which further increases the incidence 
of stress fractures, perhaps through a positive feedback mechanism [19]. Taken together, 
these experiments have suggested that suppression of bone remodeling, which prevents 
the increased porosity associated with remodeling and maintains lower strains on the 
bone, can prevent stress fractures. 
One would expect that an increase in bone remodeling would be accompanied by an 
elevation of serum or urine biochemical markers that reflect the remodeling process. In 
their prospective study, Murguia et al. [53] detected a significant increase in plasma 
hydroxyproline during the first week of military training in a group of recruits who 
subsequently presented with stress fractures, compared to those who did not. This 
showed that an initially higher bone remodeling rate is a risk factor for subsequent 
stress fractures. According to this result, preventive bisphosphonate treatment may be 
feasible for those who have increased bone remodeling at baseline. However, Bennell et 
al. [8] reported that bone remodeling in athletes who developed stress fractures was not 
different from those who did not develop stress fractures at baseline, or immediately 
prior or subsequent to the start of bone pain. The results from military recruits may not 
generalize to athletes as they represent a different population. Failure to detect increased 





may reflect overall total body bone remodeling and the tests may not be sufficiently 
sensitive enough to detect locally accelerated bone remodeling. 
Effect of bisphosphonates on fracture healing 
Over the years, there have been concerns about whether or not bisphosphonates 
interfere with fracture healing. Because they suppress bone remodeling, one might 
expect that bisphosphonates interfere with fracture repair. Li et al. [37] have reported in 
a growing rat model using incadronate that bisphosphonate treatment resulted in a larger 
fracture callus and delayed maturation of the fracture. Alendronate treatment also 
suppressed remodeling of the fracture callus in ovariectomized rats [20]. These changes 
may be secondary to inhibition of bone resorption because bone formation and 
resorption are intimately linked. Conversely, there are reassuring reports on this topic 
that show fracture callus remodeling[KK1] is not a problem in several animal models 
unless very high doses of bisphosphonates are used [7, 25].  
In contrast to these concerns, there are now several reports suggesting that 
bisphosphonates may actually enhance fracture repair, probably by stabilizing the 
fracture callus [42]. Other studies relevant to this problem include the improved 
osseointegration of metal implants in ovariectomized rats treated with ibandronate [34]. 





improved healing in distraction osteogenesis [39, 40], which conserves bone 
architecture after osteonecrosis [35, 41, 60].  
The process of bone and fracture repair consists of an anabolic (bone forming) 
response and a catabolic (bone resorbing) response. In the absence of an anabolic 
response, anti-catabolic treatment alone does not lead to union in a rat femoral critical 
defect model [42]. Bisphosphonate treatment may require anabolic conjunctive therapy 
to ensure enhanced successful repair [16, 42], but this cannot be directly applied to the 
treatment of stress fractures as they represent different features. Bisphosphonates as 
anti-catabolic agents would be considered satisfactory for the treatment of stress 
fractures, assuming that most athletes with stress fractures, except in some special 
situations e.g. female athlete triad, have a normal anabolic bone homeostatic response. 
However, if systemic bone morphogenetic proteins as anabolic agents are available, 
using them in combination with bisphosphonates [42] may be more efficacious for the 
treatment of stress fractures. 
In recent years, dosing regimens used for treating osteoporosis have evolved such that 
the time between doses has increased. From routine daily therapy, oral therapy is now 
standardized to weekly dosing for alendronate and risedronate and monthly dosing for 





month intervals, and zoledronic acid (ZA) as a once-yearly infusion [12, 21]. Previous 
preclinical studies using continuous bisphosphonate therapy may not therefore be 
relevant to such intermittent dosing regimens [5]. A single systemic dose of pamidronate 
administered at the time of fracture increased bone mineral content (BMC), volume, and 
strength of united fractures [4]. There were further increases in bone volume and 
strength when the dose of zoledronic acid was delayed by 2 weeks in a rat femoral 
critical defect model [42]. Amanat et al. [5] recently reported that delaying the single 
dose systemic zoledronic acid administration to 1 or 2 weeks after the occurrence of the 
fracture increased callus volume, callus BMC, and mechanical strength in a rat fracture 
model. 
Bisphosphonates are well known to reduce pain in a wide variety of underlying bone 
conditions, such as osteolytic metastasis, multiple myeloma, and localized transient 
osteoporosis (LTO; bone marrow edema syndrome) [61, 62]. Increased bone remodeling 
and low bone mineral density (BMD) indicate a potential role for bisphosphonate 
therapy in LTO. Miltner et al. [51] reported a case of transient osteoporosis of the 
navicular bone in a 400 m sprinter and the successful treatment with alendronate. This 
relief of bone pain is mediated not only through the inhibition of osteoclast function, but 





synthesis by a variety of cells [23].  
Recently, extracorporeal shock wave therapy was shown to be an effective method to 
treat intractable stress fractures in athletes [72]. Shock wave therapy induces 
angiogenesis-related growth factors and stimulates neovascularization, which improves 
blood supply and increases cell proliferation at the fracture site. Hausman et al. [29] 
showed that angiogenesis is essential to the very early stages of fracture healing, and 
suggested that impairment of fracture healing may be an adverse effect of clinical 
treatments with anti-angiogenic drugs. Considering the anti-angiogenic properties [26, 
65, 83], administration of nitrogen-containing bisphosphonates at the initial stage of 
fracture healing may have an adverse effect on stress fracture treatment. 
Bisphosphonates and fatigue loading 
In a short-term alendronate treatment study in rats [6], resorption space density was 
suppressed in the adapted groups receiving alendronate treatment. The lowest resorption 
space density values were found in the adapted groups that were pretreated with 
alendronate. However, work-to-failure was significantly improved in the adapted groups 
with post-treatment but not in the pre-treatment group. Therefore, pre-treatment with 
alendronate had a less advantageous effect on adaptation to fatigue when compared with 





too short to have any significant effect of alendronate on skeletal remodeling during 
functional adaptation. During post-fatigue treatment, inhibition of osteoclastic 
remodeling by alendronate may have been reduced by physiological stress [6]. In mice 
receiving both glucocorticoid and alendronate concomitantly, the expected apoptotic 
effect of bisphosphonates on osteoclasts was reduced [80]. 
Over-suppression and microdamage accumulation 
Concerns have been raised about potential over-suppression of bone remodeling during 
long-term use of bisphosphonates. Although the administration of bisphosphonates for 
athletes would be a relatively short-term treatment, physicians should at least know 
about the long-term risks[KK2]. After bone uptake, bisphosphonates are liberated again 
only when the bone in which they are deposited is resorbed. Thus, the half-life of 
bisphosphonates in bone is very long, ranging from 1 to 10 years among different 
species, and is dependent largely on the rate of bone remodeling [38]. There appears to 
be no progression of the anti-resorptive effect with time even when the compounds are 
given continuously, which suggests that bisphosphonate buried in the bone is inactive, at 
least as long as it remains sequestered there [63]. In dog ribs treated with risedronate or 
alendronate for 1 year, alendronate has been shown to inhibit normal microdamage 





in accumulation of microdamage [2, 37, 46, 47]. Bone remodeling decreased 53% and 
68% as a result of risedronate or alendronate treatments, while the corresponding 
increase in microcrack damage was 490% and 630%, respectively. In addition, the 
energy required to fracture the rib was significantly decreased by 19% in the 
alendronate treatment group. While these experiments used bisphophonate doses several 
times higher than the equivalent doses for human osteoporosis patients, it strongly 
suggests that bone remodeling is necessary to prevent fatigue microdamage from 
accumulating and weakening the bone.  
Long-term use (5-10 years) of bisphosphonates for osteoporosis therapy appears to be 
safe [11, 15]. However, there is a case series [55] that revealed severe deficiencies in 
bone formation in nine patients on long-term alendronate therapy (3-8 years). This 
resulted in an increased susceptibility to non-spinal fractures that healed poorly. In 
addition, Ott [55] speculated that long-term alendronate treatment in humans might 
impair mechanical bone strength. This suggestion was based on the apparent increase in 
the rate of vertebral fractures with prolonged treatment [75], though refuted by the 
authors of that report [76]. The induction of osteopetrotic-like lesions in a child treated 
with extremely high doses of pamidronate has also been reported [81]. Lenart et al. [36] 





pattern and hypertrophy of the diaphyseal cortex were associated with alendronate use. 
They suggested that this may result from propagation of stress fractures whose repair 
was retarded by diminished osteoclast activity and impaired microdamage repair 
resulting from prolonged use. Long-term suppression of bone remodeling by 
bisphosphonate also increased non-enzymatic cross-linking and could result in brittle 
bones [64, 68]. 
Potential adverse effects 
It is always necessary to consider the risks and benefits of any prescribed medication. 
When treating a non-life threatening disease such as stress fractures, off-label use of a 
drug demands special caution. In a case series using intravenous pamidronate for the 
treatment of stress fractures, the most common short-term side effects were nausea, 
fatigue, arthralgias, and myalgias [71]. All of the side effects resolved within 24 to 48 
hours. Since nausea was the main problem with the 90 mg dose when compared with 
the 60 mg dose, the authors recommended using a 60 mg treatment dose. On the other 
hand, in a randomized controlled study of military recruits, risedronate use for the 
prevention of stress fractures had no more side effects than a placebo treatment [50].  
Oral bisphosphonates can result in stomach upset, inflammation, and erosions of the 





can be prevented by remaining seated upright for 30 to 60 minutes after taking the 
medication. A number of cases of severe bone, joint, or musculoskeletal pain associated 
with oral bisphosphonates, alendronate and risedronate, have been reported [84]. These 
symptoms improved after discontinuation of the drug treatment. Intravenous 
nitrogen-containing bisphosphonates can give undesirable inflammatory reactions, 
including an increase in acute-phase proteins, fever, flu-like symptoms, and ophthalmic 
inflammation, after the first infusion [1, 43, 69, 73]. These are thought to occur because 
of their potential to activate human γ,δ-T cells [74]. Notably, these symptoms do not 
recur with subsequent infusions. Some of the intravenous bisphosphonates, in particular 
zoledronic acid, have nephrotoxic potential [14, 30]. 
Recently, another potential complication of these agents has surfaced. Osteonecrosis of 
the jaw (ONJ) occurred in multiple myeloma or metastatic cancer patients treated with 
intravenous bisphosphonates [10, 45, 67]. These reports have led to a growing concern 
about the safety of oral bisphosphonates in patients with osteoporosis. In a literature 
review, Pazianas et al. [58] identified 26 cases of ONJ in patients receiving oral 
bisphosphonates. Considering that millions of patients have been prescribed 
bisphosphonates for the treatment of osteoporosis, this prevalence of ONJ was relatively 





of cases were preceded by a dental surgical procedure [82]. The most common 
characteristics of those who developed ONJ were an age ≥60 years (only 1 patient was 
aged <40 years), female sex, and patients that had received previous invasive dental 
treatment [58]. At present, there is insufficient data available to construct 
evidence-based guidelines for the prevention and therapy of ONJ. In the case of 
administration of bisphosphonates to athletes, a physician should check their previous 
dental history and current dental condition, and inform the patients about the low risk of 
developing ONJ, irrespective of the route and frequency of bisphosphonate 
administration. 
Because of increased sports participation in children and adolescents, athletes with 
open physis are predisposed to stress fractures. There are some concerns about the 
impact of bisphosphonates on open physis, chondro-osseous modeling, and consequent 
growth in otherwise normal long bones. Smith et al. [70] showed that 
nitrogen-containing bisphosphonates can cause transient effects on physeal cell 
morphology and retention of cartilaginous matrix, which coincides with a growth 
disturbance (3% decrease in final long bone length), even in a short-term 6 week 
growing animal model. On the other hand, in a radiographic quantification study, Ward 





disturb physeal modeling in the distal femur throughout childhood. In a case series by 
van Persijn van Meerten [77], bisphosphonate treatment in children with open physis 
characteristically resulted in epi- and metaphyseal sclerosis, but this was a reversible 
phenomenon. However, so far there is a lack of evidence about the safe use of 
bisphosphonates for adolescent athletes with open physis. 
Although the pharmacologic activities of bisphosphonates are retained for a period of 
time after cessation of treatment, the effects of bisphosphonates are likely transient and 
may disappear once the drug is withdrawn. Therefore, short-term exposure to 
bisphosphonates for the treatment of stress fractures would not be expected to cause 
long-term deleterious effects on the skeleton [19]. 
The safety of bisphosphonates in women who are pregnant, or are of childbearing age, 
also has not been clearly established. In rat studies, alendronate was found to cross the 
placenta and accumulate in fetal bone [57], where the presence of alendronate may 
interfere with fetal bone mineralization and development. The half-life of 
bisphosphonates is proportional to bone remodeling time, which may be over 1 year in 
rats [52]. Therefore, it may take several years for a young woman to completely clear 
the drug from her body. Any harmful effects on the fetus could potentially persist for 





teratogenic effects in humans. 
Clinical intervention using bisphosphonates for stress fractures 
To date, there have been no randomized controlled studies about bisphosphonate 
treatment after stress fractures. However, a case series [71] recently reported the 
successful use of intravenous pamidronate in five intercollegiate female athletes with 
tibial stress fractures. The five subjects showed bone scan results consistent with stress 
fractures, with four of five athletes acquiring symptoms more than 5 months before 
treatment. A 30 mg test dose of pamidronate was given intravenously over 2 hours, 
followed by four additional treatments at weekly intervals in 60 mg or 90 mg amounts. 
With the initial treatment, four of five subjects were able to continue training without 
symptoms within 72 hours. Only one patient missed 3 weeks of training. The symptoms 
resolved in all five athletes within a few weeks of treatment and all remained 
asymptomatic at a minimum of 49 months of follow-up. Although no decision regarding 
the efficacy of bisphosphonates in stress fracture treatment can be made from this 
uncontrolled study with a small population, these investigators believe that the 
treatment is promising and plan to do a prospective study.  
There has been only one randomized controlled study concerning the prevention of 





male Israeli military recruits using 30 mg risedronate, or a placebo, daily for 10 days 
during the first 2 weeks of basic training, before they started any physically demanding 
training. After the initial 10-day loading dose, subjects received a 30 mg maintenance 
dose of risedronate, once a week for the next 12 weeks of the remaining 13-week 
training period. The primary outcome measure was the occurrence of a stress fracture 
during the study period. Over one third of the entire study group discontinued treatment 
because of concerns regarding potential adverse side effects, although only two soldiers 
actually reported symptoms. Despite the early dropout rate, intention-to-treat analysis 
and per-protocol analysis showed risedronate did not lower the incidence of stress 
fractures. Instead, the incidence of fatigue or stress fractures in the distal limb (tibia and 
metatarsus) was higher in subjects that received risedronate therapy before the period of 
strenuous activity, although this finding was not statistically significant. This 
observation fits with the rat model data from Barrett et al. [6]. They suggested that 
short-term pre-emptive treatment with alendronate did not protect bone from fatigue 
injury in a rat ulna cyclic fatigue loading model. Further research is warranted regarding 







Given the pathogenesis of stress fractures, there is reason to consider the potential 
role of bisphosphonates for the treatment of stress fractures based on limited 
information. However, no solid evidence-based interventions to prevent lower extremity 
stress reactions or fractures has existed so far [66]. Moreover, the present review 
confirmed that there is no conclusive evidence to prove any effect of bisphosphonates 
on stress fracture healing in humans.  
Whenever we consider a treatment plan for stress fractures, we must understand why 
the injury has occurred in the first place. A dynamic balance exists between the 
accumulation of microdamage and the host repair processes. Any intrinsic and extrinsic 
factor that disrupts this dynamic balance can increase the risk of stress fracture. Intrinsic 
factors include metabolic state, menstrual patterns, level of fitness, muscle endurance, 
anatomic alignment, and bone vascularity [27, 33]. Extrinsic factors include training 
regimens, nutritional or dietary habits, and playing equipment (footwear, playing 
surface, etc.). Understanding these underlying causes are essential before any treatment 
of stress fractures is started. 
It is estimated that >50% of a dose of intravenous bisphosphonate is bioavailable for 
incorporation into the bone matrix, compared with <1% of oral bisphosphonate [9, 22]. 





gastrointestinal side effects that oral bisphosphonates do. However, there are some 
possibilities of non-trivial side effects. Intravenous administration of clodronate and 
pamidronate require slow, prolonged infusion to avoid renal toxicity [13] and therefore 
must be undertaken in a hospital setting. This is inconvenient, labor-intensive, and 
costly and can be associated with complications [56]. Because they are 
self-administered, oral bisphosphonates provide some practical advantages. In either 
case, less frequently administered dosage regimens may enhance compliance with 
bisphosphonate treatment. Because of the relatively short-term administration of 
bisphosphonates and enthusiasm for the treatment of stress fractures, the route of 
administration may present no problems for athletes.  
Dosage and administration period of bisphosphonates for the treatment of stress 
fractures remain unsettled issues. Even at a higher dose than that used to treat human 
osteoporosis patients, any significant effect of oral bisphosphonates on skeletal 
modeling during functional adaptation would likely require a longer treatment period 
than 14 days, either before or after bone fatigue [6, 50]. In administration of intravenous 
bisphosphonates, clinically relevant doses would likely suffice for the treatment of 
stress fractures [71]. It is noteworthy that the use of intravenous bisphosphonates during 





without pain or restrictions, even though the results were from a small population 
without a control group,.  
In a rat fracture [5] or bone defect model [42], a single systemic dose and delayed 
administration of intravenous bisphosphonate, 1 or 2 weeks after making the fractures 
or defects, was found to be more effective. It is possible that by waiting until bone 
repair had commenced, the effective dose reaching the repair site may have increased 
because of greater availability of target mineral binding sites. Alternatively, the delay 
may have allowed the anabolic response to gather pace before administration of 
bisphosphonates. Conversely, an animal study [6] and clinical study [50] suggested brief 
pre-emptive treatment with alendronate before fatigue loading did not protect the 
skeleton from stress injuries. Because stress fractures do not occur in acute onset and 
bone has already commenced the repair process at the time of treatment, it is not 
necessary to delay the administration of bisphosphonates for the treatment of stress 
fractures in athletes.  
Oral bisphosphonate appears to have few side effects and no associated mortality. 
However, considering the generally healthy nature of athletes, it seems unlikely that 
short-term and clinically relevant doses of intravenous bisphosphonate treatment will 





of oral bisphosphonates are used to compensate for their low bioavailability, it may 
cause more problems in view of safety. For adolescents with open physis and women 
who are of childbearing age, the safety use of bisphosphonates has not yet established. 
Therefore, current studies of the use of bisphosphonates in young athletes should be 
limited to men without open physis. If it is found to be efficacious in the treatment of 
stress fractures, further studies in women, along with post-treatment surveillance for the 
occurrence of birth defects, should be initiated [32]. 
The question remains as to what kind of bisphosphonates should be used for the 
treatment of stress fractures. This seems likely because there is no theoretical basis for 
other bisphosphonates to behave differently. Furthermore, when not given in excess, 
many bisphosphonates have a positive effect on the mechanical properties of bone. 
However, further investigations are required to compare the different type of 
bisphosphonates regarding the effectiveness and safety in the treatment of stress 
fractures. 
Unfortunately, stress fractures occur with varying grades and locations. The relatively 
low number of each combination of grade and location seen at one clinical site makes 
prospective controlled studies difficult [31]. The proper role of bisphosphonates in 





groups randomized according to gender, fracture site, MRI findings, and activity.  
Conclusions 
Given the inhibitory action on osteoclast-mediated bone resorption, short-term 
suppression of bone remodeling using bisphosphonates could potentially treat stress 
fractures, for example tibial stress fractures that are likely to be remodeling-mediated, 
and therefore prevent stress fractures becoming regular fractures. However, there is still 
no conclusive evidence to prove any effect of bisphosphonates on stress fracture healing 
in humans. Until the results of well-designed clinical trials are available, it is prudent to 
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